EuroBiotech: More articles of note

Affimed received a payment from Genentech for reaching a preclinical milestone. (Pixabay)

> NeuroVive Pharmaceutical enrolled the first subject in a phase 1a/b trial of KL1333, a modulator of cellular levels of the NAD+ coenzyme. The drug could be used to treat primary genetic mitochondrial disorders. (Statement)

> Shares in Motif Bio rose more than 90% after it revealed it is meeting with the FDA to discuss the complete response letter for antibiotic iclaprim. (Release)

> Cytovation moved its treatment for HPV-induced warts into clinical development. The Norwegian biotech plans to start a second trial in malignant tumors later in the year. (Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Transgene secured a €20 million credit facility from a French bank. The credit extends Transgene’s cash runway out to the middle of next year. (Release—PDF)

> Affimed received a payment from Genentech for reaching a preclinical milestone. (Statement)

> Enterome teamed up with Dana-Farber Cancer Institute to develop microbiome-derived antigens as cancer immunotherapies. The alliance gives Enterome access to the cancer institute’s preclinical models. (Release)

Suggested Articles

Gilead has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Janssen and Dana Farber, who joins from Bristol-Myers Squibb.

The back-to-back pivotal successes tee Incyte up to talk to regulators about bringing the JAK inhibitor to market.

The judge also ordered Reynolds to pay $280,000 in forfeiture and around $7.5 million in restitution as punishment for his crimes.